K082851 Page 1022






GE Healthcare 510(K) Premarket Notification Submission

510(k) Summary

In accordance with 21 CFR 807.92 the following summary of information is provided:

In accordance with 21 CFR 8	307.92 the following:	summary of information i	s provided:		
Date:	September 26, 2008				
Submitter:	GE Medical Systems Information Technologies 9900 Innovation Drive Wauwatosa, WI 53226				
Primary Contact Person:	Matthias Buerger Director QA/RA - Diagnostic Cardiology GE Medical Systems Information Technologies RP-2122 9900 Innovation Drive Wauwatosa, WI 53226 Telephone: 414-721-1438 Fax: 414-721-3863 E-mail: Matthias.buerger@ge.com				
Secondary Contacts:					
	Renee Thomborough QA Leader GE Medical Systems In RP-2122 9900 Innovation Drive Wauwatosa, WI 53226 Telephone: 414-721-389 E-mail: renee thornboro	954			
Device: Trade Name:	Multilink Cable and Leadwire Systems				
Common/Usual Name:	Multilink Cable and Leadwire Systems				
Classification Names:	Patient transducer and	electrode cable			
Product Code:	890.2900	Patient transducer and electrode cable	DSA		
Predicate Device(s):	Multilink Cable and Leadwire Systems (K980582)				
Device Description:	The purpose and function of the device has not changed				
	Information Technologi patient ECG and RESF	nd Leadwires are part of the G es line of supplies and access P signals to diagnostic and mo provide a family of leadwires the	ories used to transmit nitoring equipment. The		
	end terminations are	le in multiple lengths and in r available in Snap, Banan aulti-lead individual set design	a, Mactrode, or Grabbei		





GE Healthcare 510(K) Premarket Notification Submission

	be individually removed and replaced as necessary. Mulilink leadwires are also available in a radiotranslucent version.
Intended Use:	The Intended Use has been modified to include description of users and location of use
	Multi-Link Cable and Lead Wire Systems are electrocardiograph cable systems used to transmit signals from patient surface electrodes to various electrocardiograph recorders/monitors for both diagnostic and monitoring purposes. Use is limited by the indications for use of the connected monitoring or diagnostic equipment.
	Multilink Cables and Lead Wire Systems are intended to be used by trained operators in a medical professional's environment

Technology:	The Multilink Cable and Leadwire Systems employs the same functional scientific technology as its predicate device.
Determination of Substantial Equivalence:	Summary of Non-Clinical Tests:
	The Multilink Cable and Leadwire Systems and its applications comply with voluntary standards as detailed in Section 9, 11 and 17 of this premarket submission. The following quality assurance measures were applied to the development of the system: Risk Analysis Requirements Reviews Design Reviews Testing on unit level (Module verification) Integration testing (System verification) Final acceptance testing (Validation) Performance testing (Verification) Safety testing (Verification)
	The subject of this premarket submission, Multilink Cable and Leadwire Systems, did not require clinical studies to support substantial equivalence.
Conclusion:	GE Healthcare considers the Multilink Cable and Leadwire Systems to be as safe, as effective, and performance is substantially equivalent to the predicate device(s).



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

NOV 1 9 2008

GE Medical Systems Information Technologies c/o Matthias Buerger Director QA/RA – Diagnostic Cardiology 9900 Innovation Drive Wauwatosa, WI 53226

Re: K082851

Multilink Cable and Leadwire Systems Regulation Number: 21 CFR 870.2900

Regulation Name: Transducer and Electrode Patient Cable (including connector)

Regulatory Class: II Product Code: DSA

Dated: September 26, 2008 Received: September 26, 2008

Dear Mr. Buerger:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must

Page 2 – Mr. Matthias Buerger

comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely, yours,

Bram D. Zuckerman, M.D.

Director

Division of Cardiovascular Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure



GE Healthcare 510(K) Premarket Notification Submission

510(k) Number (if	known):	,		
Device Name:	Multilink C	able and Leadv	vire Systems	
Indications for Use) :			
transmit signals fro recorders/monitors	om patient sur s for both diag	face electrodes mostic and moni	ectrocardiograph cable systems used to to various electrocardiograph itoring purposes. Use is limited by the or diagnostic equipment.	
Multilink Cables a medical profession	nd Lead Wire nal's environm	Systems are into ent.	ended to be used by trained operators in a	
Prescription Use_ (Part 21 CFR 801		AND/OR	Over-The-Counter Use_ (Part 21 CFR 801 Subpart	- C)
(PLEASE DO N	OT WRITE	BELOW THIS PAGE IF NE	S LINE - CONTINUE ON ANOTHER EDED)	₹
Concui	rence of CI	DRH, Offfice o	f Device Evaluation (ODE)	=
		1/httl]]	for Bzuderman	
		sion Sign-Of	1// 9/25 ovascular Devices	
			K08285/	